Molecular Formula | C29H31NO4 |
Molar Mass | 457.56074 |
Density | 1.217±0.06 g/cm3(Predicted) |
Boling Point | 651.5±55.0 °C(Predicted) |
pKa | 9.70±0.40(Predicted) |
Storage Condition | Room Temprature |
In vitro study | Acolbifene (ACOL) does not affect pathways of cholesterol synthesis, supporting the involvement of the clearance-related receptors in its hypocholesterolemic action. Acolbifene (EM-652) shows no agonistic activity on ERα and ERβ transcriptional function and blocks the estradiol (E2)-mediated activation of both ERα and ERβ. Acolbifene (EM-652) shows the most potent inhibition of estradiol-stimulated cell proliferation in human breast cancer cancer cells (ZR-75-1, MCF-7, T-47D) and is devoid of any intrinsic estrogenic activity. |
biological activity | Acolbifene (EM-652) is an active metabolite of em800, is an orally active pure anti-puncture hormone and selective antagonist of the estrogen receptor (ER) with an IC50 value of 0.110 nM in T-47D cells. Acolbifene (EM-652) has anti-cancer activity. |
Animal Model: | Female Sprague-Dawley rats (n = 42) initially weighing 175-200 g. |
Dosage: | 2.5 mg/kg. |
Administration: | Oral gavage, once daily for 21 d. |
Result: | Prevents tumor growth in rats. |